Numerous randomized controlled trials (RCTs) and meta-analyses have assessed the effects of supplemental dietary polyunsaturated fatty acids (PUFAs) on levels of low-density lipoprotein (LDL) and high-density lipoprotein (HDL) and the LDL/HDL ratio in patients receiving renal replacement therapy (RRT). However, results are ambiguous due to mixed reports of various nutrients used in the intervention group. We performed a network meta-analysis of RCTs to assess the effects of PUFAs on lipid profiles in patients undergoing RRT. RCTs performed before November 2021 were gathered from three databases. The means, standard deviations and the number of cases for each arm were independently extracted by two authors to form a network meta-analysis of LDL and HDL levels and the LDL/HDL ratio in a random effects model. Twenty-eight RCTs (n = 2017 subjects) were included in this study. The pooled results revealed that the combination of omega-3 fatty acids (n-3) and omega-6 fatty acids (n-6) produced significantly lower LDL (standardized mean difference (SMD) = −1.43, 95% confidence interval: −2.28 to −0.57) than the placebo. Both n-3 fatty acids (SMD = 0.78) and the combination of n-3 + n-6 (SMD = 1.09) benefited HDL significantly compared with placebo. Moreover, n-3 alone also exhibited a significantly lower LDL/HDL ratio than placebo. Collectively, PUFAs seem to be adequate nutrients for controlling lipoproteins in patients undergoing RRT. Specifically, n-3 + n-6 supplementation improved LDL levels, while n-3 improved HDL levels and the LDL/HDL ratio. However, our data provide limited information on specific dosages of PUFAs to form a concrete recommendation.
Background Numerous randomized clinical trials (RCTs) and meta-analyses have assessed the effects of supplemental dietary polyunsaturated fatty acids (PUFAs) on levels of low-density lipoproteins (LDLs) and high-density lipoproteins (HDLs), and LDL/HDL ratios in renal replacement therapy patients. However, the results have been ambiguous due to mixed reports of various nutrients used in the intervention group. We performed a network meta-analysis of randomized clinical trials to assess the effects of PUFAs on lipid profiles in renal replacement therapy patients. Methods RCTs performed prior to September 2020 were gathered from three databases. The means, standard deviations, and the number of cases for each arm were independently extracted by 2 authors for forming a network meta-analysis of LDL and HDL levels, and LDL/HDL ratios in random-effects model. Results Twenty-seven RCTs (n=1975) were included in this study. The pooled results revealed that the combination of omega-3 fatty acids (n-3) and omega-6 fatty acids (n-6) was significantly lower for the LDL (standardized mean difference [SMD]: −0.95, 95% confidence interval [CI]: −1.87 to −0.13) than the placebo, and the placebo resulted in significantly lower HDL than n-3 (SMD: −0.85, 95% CI: −1.50 to −0.20). There was no evidence of inconsistency or publication bias in the pooled results. Conclusions Collectively, PUFAs seems to be effective nutrients in controlling lipoprotein among renal replacement therapy patients. To be specific, n-3+n-6 improves LDL, and n-3 improves HDL and LDL/HDL. However, our data provide limited information on specific dosages of PUFAs to guide the clinical treatment of renal replacement therapy patients.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.